Novanta Inc (NOVTU) revenue by segment
NOVTUNasdaqMiscellaneous Electrical Machinery, Equipment & SuppliesFiscal year ends December 31Also trades as NOVT
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 5, 2026Score 11/3029% above fair value
$61.47+0.52 (+0.85%)
Close on Nov 3, 2026Market cap $5.58BP/E 94.5Yield –
Novanta Inc revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Automation Enabling Technologies | $523.46M | $508.91M | $500.84M | $497.95M | $501.34M | $496.40M | $490.62M | – | – | – | – | – | 50.8% | +4.4% |
| Medical Solutions | $506.24M | $496.03M | $479.77M | $462.36M | $455.54M | $455.30M | $458.63M | $486.47M | $454.14M | $418.33M | $382.44M | $370.24M | 49.2% | +11.1% |
| Robotics and Automation | – | – | – | – | – | – | – | $273.50M | $260.32M | $264.74M | $273.47M | $280.28M | – | – |
| Precision Medicine and Manufacturing | – | – | – | – | – | – | – | $257.61M | $268.30M | $278.68M | $282.97M | $286.77M | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Solutions | – | – | – | – | – | – | – | $47.60M | $46.22M | $44.03M | $41.88M | $38.41M | – |
| Robotics and Automation | – | – | – | – | – | – | – | $57.87M | $47.99M | $48.59M | $48.37M | $51.53M | – |
| Precision Medicine and Manufacturing | – | – | – | – | – | – | – | $54.85M | $61.48M | $68.34M | $69.28M | $72.78M | – |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $520.69M | $517.38M | $519.01M | $504.50M | $498.41M | $493.68M | $487.11M | $461.17M | $447.30M | $431.50M | $418.27M | $425.66M | 50.6% | +4.5% |
| Rest of Europe | $151.10M | $147.87M | $137.41M | $138.08M | $132.00M | $129.68M | $128.87M | $132.95M | $136.62M | $138.63M | $137.03M | $130.64M | 14.7% | +14.5% |
| Germany | $128.52M | $122.46M | $114.65M | $107.42M | $113.88M | $118.54M | $123.24M | $126.67M | $126.37M | $126.55M | $128.23M | $134.42M | 12.5% | +12.9% |
| Rest of Asia-Pacific | $104.85M | $101.04M | $97.03M | $99.80M | $102.51M | $103.18M | $107.05M | $105.53M | $102.44M | $104.50M | $105.35M | $106.76M | 10.2% | +2.3% |
| China | $99.00M | $95.32M | $93.20M | $91.36M | $91.69M | $88.93M | $84.56M | $79.82M | $70.88M | $72.72M | $73.44M | $70.63M | 9.6% | +8.0% |
| Other Countries | $25.56M | $20.88M | $19.31M | $19.16M | $18.40M | $17.69M | $18.40M | $16.62M | $16.24M | $19.56M | $19.35M | $20.36M | 2.5% | +38.9% |
From the segment and revenue-disaggregation notes of Novanta's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.
See a number that looks wrong?